SMMT logo

Summit Therapeutics (SMMT) Cash From Operations

Annual CFO

-$76.76 M
-$35.18 M-84.60%

December 31, 2023


Summary


Performance

SMMT Cash From Operations Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSMMTcash flowmetrics:

Quarterly CFO

-$30.30 M
+$2.71 M+8.20%

September 30, 2024


Summary


Performance

SMMT Quarterly CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSMMTcash flowmetrics:

TTM CFO

-$112.89 M
-$15.40 M-15.80%

September 30, 2024


Summary


Performance

SMMT TTM CFO Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherSMMTcash flowmetrics:

Cash From Operations Formula

CFO = Net Income + Non Cash Expenses + Changes In Working Capital

SMMT Cash From Operations Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year-84.6%+8.2%-15.8%
3 y3 years-59.5%-683.6%-171.5%
5 y5 years-118.7%-251.8%-370.1%

SMMT Cash From Operations Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-84.6%at low-683.6%+8.2%-216.1%at low
5 y5-year-269.8%at low-683.6%+8.2%-374.3%at low
alltimeall time-605.8%at low-188.1%+8.2%-479.8%at low

Summit Therapeutics Cash From Operations History

DateAnnualQuarterlyTTM
Sep 2024
-
-$30.30 M(-8.2%)
-$112.89 M(+15.8%)
Jun 2024
-
-$33.00 M(+9.5%)
-$97.49 M(+4.0%)
Mar 2024
-
-$30.13 M(+54.9%)
-$93.76 M(+22.2%)
Dec 2023
-$76.76 M(+84.6%)
-$19.46 M(+30.6%)
-$76.76 M(+47.3%)
Sep 2023
-
-$14.90 M(-49.1%)
-$52.11 M(+13.9%)
Jun 2023
-
-$29.27 M(+122.9%)
-$45.77 M(+28.2%)
Mar 2023
-
-$13.13 M(-353.0%)
-$35.71 M(-14.1%)
Dec 2022
-$41.58 M(-42.7%)
$5.19 M(-160.7%)
-$41.58 M(-25.7%)
Sep 2022
-
-$8.55 M(-55.5%)
-$55.95 M(-21.2%)
Jun 2022
-
-$19.22 M(+1.1%)
-$70.96 M(+0.1%)
Mar 2022
-
-$19.00 M(+107.0%)
-$70.92 M(-2.3%)
Dec 2021
-$72.59 M(+50.9%)
-$9.18 M(-61.0%)
-$72.59 M(+1.7%)
Sep 2021
-
-$23.57 M(+22.9%)
-$71.38 M(+10.7%)
Jun 2021
-
-$19.17 M(-7.2%)
-$64.46 M(+1.0%)
Mar 2021
-
-$20.67 M(+159.3%)
-$63.82 M(+32.7%)
Dec 2020
-$48.11 M(+131.8%)
-
-
Dec 2020
-
-$7.97 M(-52.1%)
-$48.11 M(+19.9%)
Sep 2020
-
-$16.65 M(-10.2%)
-$40.14 M(+25.0%)
Jun 2020
-
-$18.53 M(+273.7%)
-$32.10 M(+34.9%)
Mar 2020
-
-$4.96 M(-42.4%)
-$23.80 M(-0.9%)
Dec 2019
-$20.76 M(-40.9%)
-
-
Oct 2019
-
-$8.61 M(-15.8%)
-$24.02 M(+19.5%)
Jul 2019
-
-$10.23 M(-667.1%)
-$20.10 M(-15.3%)
Apr 2019
-
$1.80 M(-125.9%)
-$23.72 M(-32.4%)
Jan 2019
-$35.11 M(+70.6%)
-
-
Jan 2019
-
-$6.98 M(+48.6%)
-$35.11 M(-5.0%)
Oct 2018
-
-$4.70 M(-66.1%)
-$36.96 M(-19.7%)
Jul 2018
-
-$13.86 M(+44.7%)
-$46.05 M(+131.7%)
Apr 2018
-
-$9.58 M
-$19.88 M
DateAnnualQuarterlyTTM
Jan 2018
-$20.58 M(-235.6%)
-
-
Jan 2018
-
-$8.83 M(-36.0%)
-$20.58 M(+11.4%)
Oct 2017
-
-$13.79 M(-211.9%)
-$18.47 M(-162.1%)
Jul 2017
-
$12.32 M(-219.8%)
$29.72 M(+109.3%)
Apr 2017
-
-$10.28 M(+53.1%)
$14.20 M(-6.4%)
Jan 2017
$15.18 M(-162.0%)
-
-
Jan 2017
-
-$6.72 M(-119.5%)
$15.18 M(+3.5%)
Oct 2016
-
$34.41 M(-1172.5%)
$14.67 M(-156.1%)
Jul 2016
-
-$3.21 M(-65.5%)
-$26.13 M(-6.1%)
Apr 2016
-
-$9.31 M(+28.8%)
-$27.82 M(+13.7%)
Jan 2016
-$24.47 M(+47.5%)
-
-
Jan 2016
-
-$7.23 M(+13.1%)
-$24.47 M(+12.7%)
Oct 2015
-
-$6.39 M(+30.5%)
-$21.71 M(+17.4%)
Jul 2015
-
-$4.90 M(-17.9%)
-$18.48 M(-8.2%)
Apr 2015
-
-$5.96 M(+33.5%)
-$20.13 M(+21.4%)
Jan 2015
-$16.59 M(+71.3%)
-
-
Jan 2015
-
-$4.46 M(+41.1%)
-$16.59 M(+36.8%)
Oct 2014
-
-$3.16 M(-51.6%)
-$12.12 M(+35.3%)
Jul 2014
-
-$6.54 M(+170.8%)
-$8.96 M(+270.8%)
Apr 2014
-
-$2.42 M
-$2.42 M
Jan 2014
-$9.68 M(+92.3%)
-
-
Jan 2013
-$5.03 M(+32.4%)
-
-
Jan 2012
-$3.80 M(-12.3%)
-
-
Jan 2011
-$4.34 M(+63.9%)
-
-
Jan 2010
-$2.65 M(-82.0%)
-
-
Jan 2009
-$14.72 M(-8.7%)
-
-
Jan 2008
-$16.13 M(+170.6%)
-
-
Jan 2007
-$5.96 M(+266.4%)
-
-
Jan 2006
-$1.63 M(-2978.2%)
-
-
Jan 2005
$56.50 K
-
-

FAQ

  • What is Summit Therapeutics annual cash flow from operations?
  • What is the all time high annual CFO for Summit Therapeutics?
  • What is Summit Therapeutics annual CFO year-on-year change?
  • What is Summit Therapeutics quarterly cash flow from operations?
  • What is the all time high quarterly CFO for Summit Therapeutics?
  • What is Summit Therapeutics quarterly CFO year-on-year change?
  • What is Summit Therapeutics TTM cash flow from operations?
  • What is the all time high TTM CFO for Summit Therapeutics?
  • What is Summit Therapeutics TTM CFO year-on-year change?

What is Summit Therapeutics annual cash flow from operations?

The current annual CFO of SMMT is -$76.76 M

What is the all time high annual CFO for Summit Therapeutics?

Summit Therapeutics all-time high annual cash flow from operations is $15.18 M

What is Summit Therapeutics annual CFO year-on-year change?

Over the past year, SMMT annual cash flow from operations has changed by -$35.18 M (-84.60%)

What is Summit Therapeutics quarterly cash flow from operations?

The current quarterly CFO of SMMT is -$30.30 M

What is the all time high quarterly CFO for Summit Therapeutics?

Summit Therapeutics all-time high quarterly cash flow from operations is $34.41 M

What is Summit Therapeutics quarterly CFO year-on-year change?

Over the past year, SMMT quarterly cash flow from operations has changed by +$2.71 M (+8.20%)

What is Summit Therapeutics TTM cash flow from operations?

The current TTM CFO of SMMT is -$112.89 M

What is the all time high TTM CFO for Summit Therapeutics?

Summit Therapeutics all-time high TTM cash flow from operations is $29.72 M

What is Summit Therapeutics TTM CFO year-on-year change?

Over the past year, SMMT TTM cash flow from operations has changed by -$15.40 M (-15.80%)